



FACSIMILE

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone to the sender named below.

DATE: September 7, 2006

TO: Examiner Victor Oh
United States Patent and Trademark Office

NUMBER OF PAGES: 1

FAX NO: 9-1-571-273-0689

FROM: David R. Kurlandsky
PFIZER INC.
PATENT DEPARTMENT

RE: Petition Under 37 C.F.R. § 1.324 for
Correction of Inventorship in Patent
Patent No.: 6,835,751 B2
Our Reference: PC17961B

ANN ARBOR, MI 48105
(734) 622-7304

FACSIMILE NO.: (734) 622-1553

Dear Examiner Oh:

Per your telephone call of September 6, 2006. Please see attached copy of the following documentation sent to the USPTO via mail on June 1, 2006:

1. Postcard.
2. Transmittal (1 Pg).
3. Fee Transmittal (1 Pg).
4. Petition Under 37 C.F.R. § 1.324 for Correction of Inventorship in Patent, Pursuant to 35 U.S.C. § 256 (2 Pgs).
5. Inventor Statement Under 37 C.F.R. § 1.324 for Correction of Inventorship in Patent, Pursuant to 35 U.S.C. § 256 (2 Pgs – Inventor Receveur and Inventor Blakemore).
6. Assignee Statement Under 37 C.F.R. § 1.324 for Correction of Inventorship in Patent, Pursuant to 35 U.S.C. § 256 (1 Pg).

Should you have any questions or require anything further, please do not hesitate to contact me.

Very truly yours,

David R. Kurlandsky
Senior Corporate Counsel, Intellectual Property

DRK:laz
Attachment(s)

THE UNITED STATES PATENT AND TRADEMARK OFFICE IS IN RECEIPT OF A
THE FOLLOWING:

1. TRANSMITTAL (1 PG)
 2. FEE TRANSMITTAL (1 PG)
 3. PETITION UNDER 37 C.F.R. § 1.324 FOR CORRECTION OF
INVENTORSHIP IN PATENT, PURSUANT TO 35 U.S.C. § 256 (2 PGS)
 4. INVENTOR STATEMENT UNDER 37 C.F.R. § 1.324 FOR CORRECTION OF
INVENTORSHIP IN PATENT, PURSUANT TO 35 U.S.C. § 256 (2 PGS)
 5. ASSIGNEE STATEMENT UNDER 37 C.F.R. § 1.324 FOR CORRECTION OF
INVENTORSHIP IN PATENT, PURSUANT TO 35 U.S.C. § 256 (1 PG)
 6. CERTIFICATE OF MAILING
 7. RETURN POSTCARD
- AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS
NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455
IS HEREBY GIVEN.

INVENTOR(S) JUSTIN STEPHEN BRYANS, ET AL.
INVENTION ENTITLED "BICYCLIC AMINO ACIDS AS PHARMACEUTICAL
AGENTS"

June 1, 2006
DRK-LAZ

PC179618

Customer No. 28880

Confirmation No.

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/762,026

Filing Date

January 21, 2004

First Named Inventor

Justin Stephen Bryans, et al.

Art Unit


Examiner Name

Attorney Docket Number

PC17961B

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input type="checkbox"/> Statement Under 37 C.F.R. § 1.324(b)(2) for Correction of Inventorship in Patent, Pursuant to 35 U.S.C. § 256 (3 Original Documents)
Remarks Authorization to charge the fee and any additional fees as necessary or credit any overpayment to Deposit Account 23-0455 is hereby given.		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Warner-Lambert Company LLC		
Signature			
Printed name	David R. Kurlandsky		
Date	5/31/06	Reg. No.	41,505

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature



Date

5/31/2006

Typed or printed name

Linda A. Zerby

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Customer No: 28880

PTO/SB/17 (01-06)

Approved for use through 07/31/2006. OMB 0651-0052
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

**FEE TRANSMITTAL
For FY 2006** Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)
130.00**Complete if Known**

Application Number	10/762,026
Filing Date	January 21, 2004
First Named Inventor	Justin Stephen Bryans, et al.
Examiner Name	
Art Unit	
Attorney Docket No.	PC17961B

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____

Deposit Account Deposit Account Number: **23-0455** Deposit Account Name: **Warner-Lambert Company LLC**

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

- Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
- Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEES CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fee Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
0 - 20 or HP =	x 50.00	= 0.00	

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
0 - 3 or HP =	x 200.00	= 0.00	

HP = highest number of independent claims paid for, if greater than 3.

Small Entity**Fee (\$)** **Fee (\$)**

50 25

200 100

360 180

Multiple Dependent Claims**Fee (\$)** **Fee Paid (\$)**

360.00

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$)

Fee Paid (\$)

0 - 100 = 0 / 50 = (round up to a whole number) x 0.00 = 0.00

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 37 CFR 1.20(b) (37 CFR 1.324)

130.00

SUBMITTED BY	<i>DKL</i>		Registration No. 41,505	Telephone 734-622-7304
Signature			(Attorney/Agent)	Date 5/21/06
Name (Print/Type)	David R. Kurlandsky			

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Confirmation No. 3899

PC17961B

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent No. : 8,835,751 B2

Issue Date : December 28, 2004

Application No. : 10/762,026

Filed: : January 21, 2004

FOR : Bicyclic Amino Acids as Pharmaceutical Agents

Petition Under 37 C.F.R. § 1.324 for Correction of Inventorship
in Patent, Pursuant to 35 U.S.C. § 256

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Applicant hereby petitions the Director to issue a certificate correcting the inventorship of the above-referenced patent. According to 37 C.F.R. § 1.324(b), the following items are required for a grantable petition:

- (1) A statement from each person who is being added as an inventor that the inventorship error occurred without any deceptive intention on his or her part;
- (2) A statement from the current named inventors either agreeing to the change of inventorship or stating that they have no disagreement in regard to the requested change;
- (3) A statement from all assignees agreeing to the change of inventorship in the patent; and
- (4) The fee set forth in 37 C.F.R. 1.20(b).

With regard to each of the enumerated items:

1. No inventors are being added, this item is moot.
2. Statements from current named inventors. This petition includes statements from all current named inventors—David Clive Blakemore and Jean-Marie Receveur—which indicate that the current inventors have no disagreement with the request to remove Justin Stephen Bryans and Simon Andrew Osborne as inventors.
3. Statement from all assignees. This petition also includes a statement signed by Francis J. Tinney, Assistant Secretary of the Warner-Lambert Company LLC, which indicates that the

PC17961B

-2-

Warner-Lambert Company LLC agrees with the change of inventorship to remove Justin Stephen Bryans and Simon Andrew Osborne as inventors. The Warner-Lambert Company LLC is the single assignee of the entire right, title, and interest in U.S. Patent No. 6,835,751 B2. The statement by the Warner-Lambert Company LLC complies with the requirements of 36 CFR § 3.73(b).

4. Petition fee. Applicant has enclosed a Fee Transmittal authorizing the Patent Office to charge Applicant's deposit account \$130.00, which is the processing fee set forth in 37 CFR 1.20(b) for correcting inventorship in a patent.

Applicant believes that all fees associated with the filing of the present petition have been identified in the fee transmittal that accompanies this paper. However, if any additional fees are required in connection with the filing of this petition, and such fees have not been identified in the accompanying fee transmittal, please charge deposit account number 23-0455.

Respectfully submitted,

Dated: 5/31/06



David R. Kurlandsky
Registration No. 41,505
Warner-Lambert Company LLC
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-7304
Facsimile: (734) 622-1563

Encl. Statement from David Clive Blakemore
Statement from Jean-Marie Receveur
Statement from the Warner-Lambert Company, LLC

PC17961B

Confirmation No. 3899

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent No. : 6,835,751 B2

Issue Date : December 28, 2004

Application No. : 10/762,026

Filed: : January 21, 2004

FOR : Bicyclic Amino Acids as Pharmaceutical Agents

Statement Under 37 C.F.R. § 1.324(b)(2) for Correction of Inventorship
in Patent, Pursuant to 35 U.S.C. § 256

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

As current named inventor on U.S. Patent 6,835,751 B2, I have no disagreement in regard to removing
Justin Stephen Bryans and Simon Andrew Osborne as inventors.

Respectfully submitted,

Dated: 22/05-06
Jean-Marie Receveur

PC17961B

Confirmation No. 3899

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent No. : 6,835,751 B2

Issue Date : December 28, 2004

Application No. : 10/762,026

Filed: : January 21, 2004

FOR : Bicyclic Amino Acids as Pharmaceutical Agents

Statement Under 37 C.F.R. § 1.324(b)(2) for Correction of Inventorship
In Patent, Pursuant to 35 U.S.C. § 256

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

As current named inventor on U.S. Patent 6,835,751 B2, I have no disagreement in regard to removing
Justin Stephen Bryans and Simon Andrew Osborne as inventors.

Respectfully submitted,

Dated: 24th MAY 2006D and Clive Blakemore
David Clive Blakemore

Confirmation No. 3899

PC17961B

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent No. : 6,835,751 B2

Issue Date : December 28, 2004

Application No. : 10/762,026

Filed: : January 21, 2004

FOR : Bicyclic Amino Acids as Pharmaceutical Agents

Statement Under 37 C.F.R. § 1.324(b)(2) for Correction of Inventorship
in Patent, Pursuant to 35 U.S.C. § 256

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I, Francis J. Tinney, am authorized to act on behalf of the Warner-Lambert Company LLC, which agrees to the removal of Justin Stephen Bryans and Simon Andrew Osborne as inventors on U.S. Patent No. 6,835,751 B2. The Warner-Lambert Company LLC, is the single assignee of the entire right, title, and interest in U.S. Patent No. 6,835,751 B2, as evidenced by assignments recorded in the United States Patent and Trademark Office on reel 010424 and frame number 0267 and reel 012555 and frame 0598.

Respectfully submitted,

Dated: 5/31/2006

Francis J. Tinney, Assistant Secretary
Warner-Lambert Company LLC